Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | PepGen Inc. |
|---|---|
| Ticker | PEPG |
| CIK | 0001835597 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 106,1 Mio. USD |
| Beta | 2,34 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -89,655,000 | -2.12 | 173,907,000 | 147,444,000 | |
| 2025-09-30 | 10-Q | -18,026,000 | -0.52 | 190,057,000 | 163,140,000 | |
| 2025-06-30 | 10-Q | -23,087,000 | -0.70 | 102,242,000 | 71,158,000 | |
| 2025-03-31 | 10-Q | -30,202,000 | -0.92 | 127,393,000 | 91,805,000 | |
| 2024-12-31 | 10-K | -89,981,000 | -2.85 | 150,883,000 | 118,620,000 | |
| 2024-09-30 | 10-Q | -21,384,000 | -0.66 | 170,234,000 | 137,455,000 | |
| 2024-06-30 | 10-Q | -28,335,000 | -0.87 | 193,510,000 | 155,040,000 | |
| 2024-03-31 | 10-Q | -18,020,000 | -0.63 | 207,000,000 | 178,999,000 | |
| 2023-12-31 | 10-K | -78,626,000 | -3.30 | 143,052,000 | 108,421,000 | |
| 2023-09-30 | 10-Q | -23,290,000 | -0.98 | 164,271,000 | 125,865,000 | |
| 2023-06-30 | 10-Q | -19,522,000 | -0.82 | 182,085,000 | 147,284,000 | |
| 2023-03-31 | 10-Q | -16,319,000 | -0.69 | 201,041,000 | 164,843,000 | |
| 2022-12-31 | 10-K | -69,104,000 | -4.42 | 217,440,000 | 179,631,000 | |
| 2022-09-30 | 10-Q | -18,607,000 | -0.79 | 208,461,000 | 192,942,000 | |
| 2022-06-30 | 10-Q | -17,315,000 | -1.23 | 230,796,000 | 210,219,000 | |
| 2022-03-31 | 10-Q | -18,246,000 | -18.94 | 131,879,000 | -49,587,000 | |
| 2021-12-31 | 10-K | -27,281,000 | -30.27 | 143,641,000 | -32,082,000 | |
| 2021-09-30 | 10-Q | -8,112,000 | -9.07 | -25,606,000 | ||
| 2021-06-30 | 10-Q | -5,389,000 | -6.03 | -17,845,000 | ||
| 2021-03-31 | 10-Q | -6,636,000 | -12,782,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | STRECK PAUL | Officer, EVP, Head of R&D | Open Market Sale | -1,832 | 6.23 | -11,413.36 | -0,3% | |
| 2026-03-04 | McArthur James G | Director, Officer, President and CEO | Open Market Sale | -131 | 6.33 | -828.58 | 0,0% | |
| 2026-03-04 | McArthur James G | Director, Officer, President and CEO | Open Market Sale | -5,144 | 6.23 | -32,047.12 | -0,9% | |
| 2026-03-04 | STRECK PAUL | Officer, EVP, Head of R&D | Open Market Sale | -47 | 6.29 | -295.54 | 0,0% | |
| 2026-03-04 | Donnelly Noel | Officer, Chief Financial Officer | Open Market Sale | -52 | 6.33 | -328.90 | 0,0% | |
| 2026-03-04 | Donnelly Noel | Officer, Chief Financial Officer | Open Market Sale | -2,032 | 6.23 | -12,659.36 | -0,4% | |
| 2025-09-30 | Oxford Science Enterprises plc | Open Market Purchase | 200,000 | 3.20 | 640,000.00 | +18,8% | ||
| 2025-09-26 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 9,375,000 | 3.20 | 30,000,000.00 | +879,3% | |
| 2025-05-30 | STRECK PAUL | Officer, EVP, Head of R&D | Open Market Purchase | 8,375 | 1.24 | 10,393.38 | +0,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.